Updates are available Correction dated 2025-03-11
Click to view Correction: https://doi.org/10.1186/s13722-025-00556-z
-
Authors
Xu, Kevin Y.
Bello, Jennifer K.
Buss, Joanna
Jones, Hendrée E.
Bierut, Laura J.
Stwalley, Dustin
Szlyk, Hannah S.
Martin, Caitlin E.
Kelly, Jeannie C.
Carter, Ebony B.
Krans, Elizabeth E.
Grucza, Richard A.
-
Funding
Funding for this research was provided by:
National Institute on Drug Abuse (NIH K12 DA041449, NIH K12 DA041449, NIH K12 DA041449, NIH K12 DA041449)
Washington University in St. Louis (CADRA Grant, CADRA Grant, CADRA Grant, CADRA Grant)
- License Information
-
More Information
Article History
Received: 22 June 2024
Accepted: 16 December 2024
First Online: 6 January 2025
Change Date: 11 March 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13722-025-00556-z
Declarations
:
: Not applicable.
: Not applicable.
: Dissemination to study participants and or patient organizations is not possible or applicable due to the de-identified nature of our data.
: Oral Presentation, AMERSA Annual Meeting, November 4 2023, Washington DC, USA
: Dr Grucza reported receiving grants from the NIH and Arnold Ventures LLC during the conduct of the study, consulting for Janssen Pharmaceuticals, and receiving personal fees for grant reviews from the NIH outside the submitted work. Dr. Krans is an investigator on grants to Magee-Women’s Research Institute from the National Institutes of Health, Gilead, and Merck outside of the submitted work. These funding sources did not influence the design of the present study and the interpretation of data. The authors alone are responsible for the content and writing of this paper.
